GO
Loading...

Tesaro: Next big thing in biotech?

Monday, 13 Jan 2014 | 5:45 PM ET

Lonnie Moulder, Tesaro CEO, discusses the drug Rolapitant, which controls the effects of chemotherapy. Moulder says it's not about market share but about accessing patients who should receive the drug.